A Safe Stock to Buoy Up Your Portfolio

More than halfway into 2021, and so much has transpired in the investing world.

We witnessed a historical short squeeze, the unprecedented rise of cryptocurrencies, and even the battle among billionaires on who would get to explore outer space first. 

The stock market has been quite volatile over the past months, and the fears that we’re barreling towards another downturn, as fueled partly by concerns on inflation, continue to haunt us.

Amid the noise and the chaos, it’s critical to bear in mind one of the most important rules of investing: Buying and holding shares of stable companies for a long period usually reaps great returns.

While no one knows what the rest of 2021 holds, there are still remarkable companies that are worth buying and holding through the course of the next few months.

One such company is Eli Lilly (LLY).

The greatest strength of Eli Lilly is the way it handles its diverse pipeline. While it continues to expand its reach to cover more and more markets, the company also ensures that it doesn’t neglect its well-established niches.

For instance, Eli Lilly continues to boost its diabetes and obesity sector. One of the company’s most promising projects is a new drug called Tirzepatide, which targets these health conditions.

This is now undergoing Phase 3 clinical trials, and if successful, could rake in $7.8 billion in sales for Eli Lilly.

It’s also developing a once-a-week insulin, called Basal Insulin Fc, which would be administered to patients with Type 2 diabetes.

If approved, this would be a massive breakthrough considering that the patients typically need to take insulin daily.

Another effort to shore up its diabetes franchise is Eli Lilly’s decision to buy a next-generation biotechnology company called Protomer for a whopping $1 billion.

Although Protomer has only been in operations for six years, the private company has already developed incredible technology in the diabetes sector.

The most remarkable achievement it has so far is a platform that can create glucose-response insulins, which can sense the body’s sugar levels and then get activated automatically throughout the day.

Although this is still in its early stages, this technology could drastically reduce the risk of hypo- and hyperglycemia among diabetes patients.

Eli Lilly’s deal with Protomer follows in the footsteps of the leading diabetes company worldwide, Novo Nordisk (NVO), which also struck a similar agreement worth $800 million with another biotech startup in 2018.

Aside from diabetes and obesity, Eli Lilly has also been working on dominating in the Alzheimer’s disease space.

When the FDA granted Biogen’s (BIIB) Alzheimer candidate Aduhelm with accelerated approval, it also opened a door for Eli Lilly.

Even prior to this approval, Eli Lilly has already been working on its own candidates, Donanemab. What the Biogen approval provides is a higher chance of positive review for Eli Lilly’s candidate.

In fact, mere weeks after Aduhelm’s accelerated approval, Eli Lilly announced that it would submit an application for the same authorization by the end of 2021.

At this point, the treatment holds a Breakthrough Therapy designation from the FDA.

Given this, it’s presumably a shoo-in for approval soon, thereby adding a new growth driver to the company’s extensive arsenal.

Other than the two, Roche (RHHBY) is also expected to throw its hat in the ring with its Alzheimer’s candidate Gantenerumab.

Eli Lilly’s current lineup of products is definitely worth mentioning as well.

In the first quarter of 2021, the company’s revenue climbed by 16% year over year to hit $6.9 billion.

One of its top performers is its diabetes drug Trulicity, which recorded an 18% jump in sales to reach $1.5 billion.

In terms of its bottom line, Eli Lilly projects its adjusted earnings to increase between 15% and 18% year over year in 2021.

Looking at its financials, it’s clear that Eli Lilly’s current portfolio and pipeline are favorably positioned to deliver strong financial results year after year.

Although the company hasn’t exactly catapulted to unprecedented heights, it has shown stable and consistent growth as well as notable gross margins of over 70%.

It has consistently outperformed the markets in the past five years, climbing close to 200%.

This is the reason why regardless of the ups and downs of the market, investors can easily count on this stock to climb continuously in the long run.